A fresh licensing deal tidies up years of work between the two companies.
ApexOnco Front Page
Recent articles
And that could affect the drug's third-line accelerated approval.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
